Quality of life during menstruation in patients with inherited bleeding disorders. Haemophilia, 1998; 4(6): 836–41., , , et al.
Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey. Haemophilia, 2000; 6(6): 643–8., , , et al.
Gynecological disorders and psychological problems in 184 women with von Willebrand disease (vWD). Haemophilia, 1998; 4(3): 293.
A revised model of platelet aggregation. J. Clin. Invest., 2000; 105(6): 783–91., , , et al.
Integrin signaling: the platelet paradigm. Blood, 1998; 91(8): 2645–57., and
Collagen receptor signalling in platelets: extending the role of the ITAM. Immunol. Today, 1998; 19(6): 260–4. and
Reference intervals for plasma levels of fibronectin, von Willebrand factor, free protein S and antithrombin during third-trimester pregnancy. Scand. J. Clin. Lab. Invest., 2004; 64(1): 31–40., , , et al.
Pregnancy in women with von Willebrand's disease or factor XI deficiency. Br. J. Obstet. Gynaecol., 1998; 105(3): 314–21., , , et al.
Pregnancy in women with different types of von Willebrand disease. Obstet. Gynecol., 1986; 68(2): 282–5., , , et al.
Haemostasis in normal pregnancy. Thromb. Haemost., 1984; 52(2): 176–82., , , et al.
Inherited bleeding disorders in obstetrics and gynaecology. Br. J. Obstet. Gynaecol., 1999; 106(1): 5–13., and
Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. Eur. J. Obstet. Gynecol. Reprod. Biol., 1997; 73(1): 31–6., , , et al.
Pharmacokinetics, efficacy and safety of Humate-P in von Willebrand disease. Haemophilia, 1998; 4(Suppl 3): 33–9., and
A serial study of coagulation factors XII, XI and X in plasma in normal pregnancy and in pregnancy complicated by pre-eclampsia. Br. J. Obstet. Gynaecol., 1976; 83(8): 636–9.
Changes in factor XI (plasma thromboplastin antecedent) levels during pregnancy. Am. J. Obstet. Gynecol., 1973; 116(8): 1114–6., and
The coagulation and fibrinolytic enzyme system in pregnancy and in the puerperium. Eur. J. Obstet. Gynecol. Reprod. Biol., 1982; 13(3): 177–97. and
Plasma thromboplastin antecedent (Factor Xi) in the neonate. J. Pediatr., 1965; 66: 747–52. and
Functional and immunologic protein S in normal pregnant women and in full-term newborns. Thromb. Haemost., 1989; 61(3): 474–8., , , et al.
Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb. Haemost., 1998; 79(6): 1166–70., , , et al.
New reference values for routine blood samples and human neutrophilic lipocalin during third-trimester pregnancy. Scand. J. Clin. Lab. Invest., 2001; 61(8): 583–92., , , et al.
APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb. Haemost., 1999; 81(4): 527–31., , , et al.
TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br. J. Haematol., 2001; 115(1): 150–2., , , et al.
Evaluation of six markers of haemostatic systems in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br. J. Obstet. Gynaecol., 1993; 100(5): 416–20., , , et al.
Plasminogen activators and inhibitors in normal late pregnancy, postpartum and in the postnatal period. Int. J. Gynaecol. Obstet., 1992; 38(1): 9–18., , , et al.
Application of indicators, predictors and diagnostic indices in coagulation disorders. I. Evaluation of a self-administered questionnaire with binary questions. Methods Inf. Med., 1980; 19(4): 194–200., , , et al.
Menorrhagia from a haematologist's point of view. Part I: initial evaluation. Haemophilia, 2002; 8(3): 330–8.
Menorrhagia from a haematologist's point of view. Part II: management. Haemophilia 2002; 8(3): 339–47. and
The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch. Surg., 1998; 133(2): 134–9., , , et al.
Utility of the PFA-100™ for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia, 2001; 7(2): 170–9.
Evaluation of a Platelet Function Analyser (PFA-100™) in patients with a bleeding tendency. Swiss Med. Wkly., 2002(132): 443–8., , , et al.
Roa, A. Disorders of platelet function. In Consultative Hemostasis and Thrombosis. 1st edn. Philadelphia: W. B. Saunders; 2002. pp. 133–48., and , eds.
Celecoxib does not affect the antiplatelet activity of aspirin in healthy volunteers. J. Clin. Pharmacol., 2002; 42(9): 1027–30., , , et al.
Rofecoxib does not compromise platelet aggregation during anesthesia and surgery. Can. J. Anaesth., 2003; 50(10): 1004–8., , , et al.
Rofecoxib exerts no effect on platelet plug formation in healthy volunteers. Clin. Exp. Rheumatol., 2003; 21(2): 229–31., , , et al.
Clopidogrel. Drugs, 1997; 54(5): 745–50; discussion p. 751. and
Intravascular hemolysis, thrombocytopenia and other hematologic abnormalities associated with severe toxemia of pregnancy. N. Engl. J. Med., 1954; 250(3): 89–98., , , et al.
Platelet and leukocyte counts in pregnancy. JAMA, 1979; 242(24): 2696–8. and
Von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia. Obstet. Gynecol., 2001; 97(4): 630–6., , , et al.
Epidemiological investigation of the prevalence of von Willebrand's disease. Blood, 1987; 69(2): 454–9., and
On the value of menorrhagia as a predictor for coagulation disorders. Am. J. Hematol., 1996; 53(4): 234–8., , , et al.
Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract. Res. Clin. Haematol., 2001; 14(2): 257–79.
Shear-dependant changes in the three-dimensional structure of human von Willebrand factor. Blood, 1996; 88: 2939–50.
Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood, 1999; 94(1): 172–8., and
Adenosine diphosphate induces binding of von Willebrand factor to human platelets. Nature, 1982; 297(5862): 154–6. and
Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J. Clin. Invest., 2000; 106(3): 385–92., , , et al.
Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. J. Clin. Invest., 1998; 101(2): 479–86., , , et al.
Seremetis S. and Afshani, V. Management of bleeding disorders in pregnancy. In Consultative Hemostasis and Thrombosis. 1st edn. Philadelphia: W. B. Saunders; 2002. pp. 437–48., and , eds.
Acquired von Willebrand's disease. Ir. J. Med. Sci., 1998; 167(2): 81–5., , , et al.
Acquired von Willebrand syndrome – report of 10 cases and review of the literature. Haemophilia, 1999; 5(5): 318–26. and
Acquired von Willebrand's syndrome causing a hemorrhagic diathesis in a patient with hypothyroidism. Thyroid, 1995; 5(5): 399–401., and
Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br. J. Haematol., 2000; 111(4): 1236–9., and
Manual of Coagulation Disorders. 1st edn. Malden, MA: Blackwell Science; 2001.
Pregnancy in women with type 1 von Willebrand disease caused by heterozygosity for von Willebrand factor mutation C1130F. Thromb. Haemost., 2000; 84(2): 351–2., , , et al.
Obstetric and gynaecological aspects of von Willebrand disease. Best Pract. Res. Clin. Haematol., 2001; 14(2): 381–99.
Von Willebrand's disease complicating second-trimester abortion. Obstet. Gynecol., 1980; 55(2): 253–4., ,
Type 2 von Willebrand disease causing defective von Willebrand factor-dependent platelet function. Best. Pract. Res. Clin. Haematol., 2001; 14(2): 349–64., , , et al.
Von Willebrand disease: a database of point mutations, insertions, and deletions. For the Consortium on von Willebrand Factor Mutations and Polymorphisms, and the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb. Haemost., 1993; 69(2): 177–84. and
Classification of variant von Willebrand's disease subtypes by analysis of functional characteristics and multimeric composition of factor VIII/von Willebrand factor. Ann. NY. Acad. Sci., 1981; 370: 205–9. and
Incidence of severe von Willebrand's disease. N. Engl. J. Med., 1982; 307(2): 127., and
Atherosclerosis and von Willebrand factor. I. Prevalence of severe von Willebrand's disease in western Europe and Israel. Br. J. Haematol., 1984; 57(1): 163–9., , , et al.
Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. Thromb. Haemost., 1999; 82(5): 1456–61., , , et al.
Changes in von Willebrand factor and Factor VIII during the menstrual cycle. Thromb. Haemost., 2002; 87(6): 1082–3., , , et al.
Variations in factor VIII during the menstrual cycle in normal women. N. Engl. J. Med., 1980; 302(19): 1093–4., , , et al.
On laboratory problems in diagnosing mild von Willebrand's disease. Am. J. Hematol., 1992; 40(2): 117–20., , , et al.
Laboratory diagnosis of congenital von Willebrand disease. Semin. Thromb. Hemost., 2002; 28(2): 173–90., , , et al.
Analysis of the complexity of the multimeric structure of factor VIII related antigen/von Willebrand protein using a modified electrophoretic technique. J. Clin. Pathol., 1983; 36(8): 915–9. and
Investigation and management of haemorrhagic disorders in pregnancy. Haemostasis and Thrombosis Task Force. J. Clin. Pathol., 1994; 47(2): 100–8., , , et al.
Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract. Res. Clin. Haematol., 2001; 14(2): 365–79.
Advances in the therapy of von Willebrand disease. Haemophilia, 2002; 8(3): 301–7., , , et al.
How I treat patients with von Willebrand disease. Blood, 2001; 97(7): 1915–19.
Von Willebrand's disease and pregnancy: management during delivery and outcome of offspring. Am. J. Obstet. Gynecol., 1986; 155(3): 618–24., and
Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years. Blood, 1997; 90(7): 2515–21.
Hemostatic drugs. N. Engl. J. Med., 1998; 339(4): 245–53.
Successful use of desmopression (DDAVP) in pregnant women with inherited storage pool disease. Haemophilia, 2000; 6: 241., and
DDAVP treatment of diabetes insipidus during pregnancy and the post-partum period. Acta Endocrinol., 1981; 97: 23–5., and
The use of prophylactic desmopressin (DDAVP) in labor to prevent hemorrhage in a patient with Ehlers-Danlos syndrome. NY State J. Med., 1991; 91(6): 268–9., , , et al.
Pregnancy management and successful outcome of Ehlers-Danlos syndrome type IV. Am. J. Perinatol., 1987; 4(2): 134–7., , , et al.
DDAVP use during pregnancy: an analysis of its safety for mother and child. Obstet. Gynecol. Surv., 1998; 53(7): 450–5.
Heterogeneity of type I von Willebrand disease: evidence for a subgroup with an abnormal von Willebrand factor. Blood, 1985; 66(4): 796–802., , , et al.
Impact, diagnosis and treatment of von Willebrand disease. Thromb. Haemost., 2000; 84(2): 160–74., , , et al.
Biological effect of desmopressin in eight patients with type 2N (‘Normandy’) von Willebrand disease. Collaborative Group. Br. J. Haematol., 1994; 88(4): 849–54., , , et al.
Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type II B von Willebrand's disease. N. Engl. J. Med., 1983; 309(14): 816–21., , , et al.
Congenital disorders of platelet function. Clin. Obstet. Gynecol. 1999; 42(2): 390–405. and
Epidurals, spinals and bleeding disorders in pregnancy: a review. Anaesth. Intensive Care, 1990; 18(3): 319–26.
von Willebrand disease: recent advances in pathophysiology and treatment. Am. J. Med. Sci., 1998; 316(2): 77–86. and
Inhibitory effect of peak 2–4 of uremic middle molecules on platelet aggregation. Eur. J. Haematol., 1987; 39(3): 197–202., , , et al.
Inhibition of platelet function by uremic middle molecules. Nephron, 1985; 40(4): 423–8., , , et al.
Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol. Dial. Transplant, 2003; 18(9): 1834–41., , , et al.
Kunicki T. J. Platelet immunology. In Hemostasis and Thrombosis: Basic Principles & Clinical Practice. 4th edn. Philadelphia: Lippincott Williams & Wilkins; 2001, pp. 461–77., , , et al., eds.
Inherited bleeding disorders: disorders of platelet adhesion and aggregation. Crit. Rev. Oncol. Hematol., 2004; 49(1): 1–35.
Bernard-Soulier syndrome in pregnancy: case report and review of the literature. Clin. Lab. Haematol., 1998; 20(2): 125–8., , , et al.
Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?Pathophysiol. Haemost. Thromb., 2002; 32(Suppl. 1): 37–40.
Use of recombinant factor VIIa for bleeding in children with Glanzmann thrombasthenia. Pediatr. Hematol. Oncol., 2003; 20(6): 435–8., , , et al.
Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin. Hematol., 2001; 38(4 Suppl. 12): 21–5., , , et al.
The use of recombinant factor VIIa in children with inherited platelet function disorders. Br. J. Haematol., 2003; 121(3): 477–81., ,
Severe factor VIII and factor IX deficiency in females. Am. J. Med., 1978; 65(4): 637–48. and
High gene frequency of factor XI (PTA) deficiency in Ashkenazi Jews. Blood, 1978; 51(6): 1223–8.
Factor XI deficiency in the French Basque Country. Haemophilia, 1999; 5(3): 187–90., , , et al.
Factor XI deficiency in women. Am. J. Hematol., 1999; 60(1): 48–54., and
Inheritance and bleeding in factor XI deficiency. Br. J. Haematol., 1988; 69(4): 521–8., , , et al.
Thrombogenic potential of factor XI concentrate. Lancet, 1994; 344(8924): 748–9., , , et al.
Roberts, H. and Escobar, M. Less common congenital disorders of hemostasis. In Consultative Hemostasis and Thrombosis. Philadelphia: W. B. Saunders; 2002, pp. 57–73., and , eds.
A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb. Haemost., 1981; 45(3): 200–3. and
Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment. Thromb. Haemost., 1995; 73(1): 1–5., and
Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors. Br. J. Haematol., 2003; 121(1): 21–35., , , et al.
Suggestions for the management of factor VIII inhibitors. Haemophilia, 2000; 6(Suppl. 1): 52–9., , , et al.
Ewenstein B., Putnam K. and Bohn R. Nonhemophilic inhibitors of coagulation. In Consultative Hemostasis and Thrombosis. Philadelphia: W. B. Saunders; 2002, pp. 75–90., and , eds.
Continuous infusion of porcine factor VIII in the management of patients with factor VIII inhibitors. Am. J. Hematol., 1997; 56(2): 112–8., , , et al.
Acquired hemophilia. Trans. Assoc. Am. Physicians, 1969; 82: 388–97. and
Suppression of an antibody to factor VIII by a combination of factor VIII and cyclophosphamide. Blood, 1971; 37(4): 381–7.
Corticosteroid therapy for acquired F VIII: C inhibitors. Br. J. Haematol., 1981; 48(4): 635–42., and
A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood, 1995; 86(2): 797–804., , , et al.
Intravenous immunoglobulin in the treatment of spontaneously acquired factor VIII: C inhibitors. Am. J. Med., 1991; 91(5A): 35–9(S)., , , et al.